These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 12903714)
1. CD34+ cells in hematopoietic stem cell transplantation. Demirer T Adv Exp Med Biol; 2003; 534():107-18. PubMed ID: 12903714 [No Abstract] [Full Text] [Related]
2. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma. Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456 [TBL] [Abstract][Full Text] [Related]
3. Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF. Schiødt I; Knudsen LM; Jensen L; Nikolajsen K; Gaarsdal E; Johnsen HE Bone Marrow Transplant; 1998 Jun; 21(11):1167-9. PubMed ID: 9645584 [No Abstract] [Full Text] [Related]
4. Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections. Gambell P; Herbert K; Dickinson M; Stokes K; Bressel M; Wall D; Harrison S; Prince HM Biol Blood Marrow Transplant; 2012 May; 18(5):763-72. PubMed ID: 22227589 [TBL] [Abstract][Full Text] [Related]
5. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related]
6. [In vivo effect of rhG-CSF on the CXCR-4 expression of hematopoietic progenitor or stem cells in bone marrow and peripheral blood]. Zhao XY; Chang YJ; Huang XJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):857-60. PubMed ID: 16277858 [TBL] [Abstract][Full Text] [Related]
7. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients. Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967 [TBL] [Abstract][Full Text] [Related]
9. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715 [TBL] [Abstract][Full Text] [Related]
10. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial. Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK Biol Blood Marrow Transplant; 2013 Mar; 19(3):460-7. PubMed ID: 23201472 [TBL] [Abstract][Full Text] [Related]
11. Ex vivo manipulations of CD34+ peripheral blood progenitor cells. Brugger W; Scheding S; Vogel W; Bock T; Bühring HJ; Ziegler B; Kanz L Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S5-7. PubMed ID: 8899158 [No Abstract] [Full Text] [Related]
13. Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product. Holm M J Hematother; 1998 Apr; 7(2):111-3. PubMed ID: 9597568 [No Abstract] [Full Text] [Related]
14. The mobilization with delayed G-CSF administration after standard induction chemotherapy and single standard volume apheresis can supply adequate amount of CD34(+) cells in patients with breast cancer. Arpaci F; Kömürcü S; Oztürk B; Ozet A; Kinalp C; Yalçin A Haematologica; 2001 Feb; 86(2):E01. PubMed ID: 11224504 [No Abstract] [Full Text] [Related]
15. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization. Sancho JM; Morgades M; Grifols JR; Juncà J; Guardia R; Vives S; Ferrà C; Batlle M; Ester A; Gallardo D; Millà F; Feliu E; Ribera JM Cytotherapy; 2012 Aug; 14(7):823-9. PubMed ID: 22540329 [TBL] [Abstract][Full Text] [Related]